Scope and Claim Coverage for US Patent 10,159,682 (Crystalline Form III of Cortexolone-17α-Propionate)
US 10,159,682 is a crystalline-form IP asset centered on crystalline form III of cortexolone-17α-propionate (DRX-defined). The claims are method claims for treating specified skin/cutaneous pathologies by administering an effective amount of that crystalline form, with dependent claim fallbacks that (i) limit use to topical administration, (ii) restrict the treated indication set, and (iii) broaden coverage to pharmaceutical compositions that include physiologically acceptable excipients, optional solubilized cortexolone-17α-propionate, and/or mixtures with other crystalline forms (I, II, IV). The claim set is designed to capture both “neat” crystalline material and finished dosage forms where crystalline form III is present, including gel/cream/ointment/paste formats, and to enforce DRX-based identity to distinguish the polymorph from other forms.
What does US 10,159,682 claim scope cover for crystalline form III of cortexolone-17α-propionate?
Answer (scope in one line): It covers treating acne, androgenetic alopecia, hirsutism, and seborrheic dermatitis by administering DRX-defined crystalline form III of cortexolone-17α-propionate, either directly or in compositions (often topical) with specified excipients and optional solubilized drug and/or other polymorphs.
Core claim architecture: “method of treating” anchored to a polymorph definition
Claims 1 and 7 define the invention as a treatment method that hinges on the drug being “crystalline form III of cortexolone-17α-propionate” characterized by a powder X-ray diffraction (PXRD) pattern.
Claim 1 (method, crystalline drug)
- Treats: pathology affecting skin and/or cutaneous appendages
- Pathology set (explicit): acne, androgenetic alopecia, hirsutism, seborrheic dermatitis
- Administers: an effective amount of crystalline form III of cortexolone-17α-propionate
- Identity definition:
- “a DRX as shown in FIG. 7, 10, or 13; or”
- “a DRX with at least peaks at about 6.2, 12.6, 14.1, 14.3, 16.0, 22.4, and 23.7 degrees 2theta.”
Claim 7 (method, crystalline in a composition)
- Similar therapeutic scope as Claim 1
- Administers: a composition comprising at least one physiologically acceptable excipient + crystalline form III
- Same DRX characterization language
Dependent claims tighten route, indication, and formulation composition
The dependents mainly do three things:
- Restrict administration to topical use (Claim 2 / Claim 8).
- Enumerate the indication by dependent mapping (Claims 3–6 and 9–12).
- Expand formulation coverage: excipient lists, dosage form formats, optional solubilized drug, and mixtures with other polymorphs (Claims 13–20).
How are the claims defined by the DRX/PXRD peaks and FIG references?
The polymorph “gate” in this patent is a diffraction-pattern test. The claims are written to be satisfied when the accused material matches either:
- the diffraction pattern shown in specific figures (FIG. 7, 10, or 13), or
- a diffraction pattern that contains at least peaks at specified 2θ values (6.2, 12.6, 14.1, 14.3, 16.0, 22.4, 23.7).
Practical enforcement consequence
This claim drafting typically supports infringement arguments that focus on analytical characterization of the drug substance (or a formulation bulk where the active is crystalline form III). A challenger would need to show the supplied active is not “crystalline form III” as defined by the DRX criteria.
Claim sensitivity to diffraction tolerances
The peaks are “at about” specified 2θ values, and the claim also allows matching to “DRX as shown in FIG. 7, 10, or 13.” That combination generally provides some leeway in measurement variability and supports a broader read than a strict single-value lattice.
Coverage edge: mixed solids and blends
Claim 19 and Claim 20 explicitly contemplate mixtures where crystalline forms I, II, and/or IV are also present. That matters for design-around attempts because a supplier cannot avoid coverage merely by co-formulating or co-manufacturing multiple polymorphs, as long as crystalline form III is present in the specified co-existing amounts.
Which indications are covered by US 10,159,682 and how broadly?
Covered indication set (expressly named in independent claims via the pathology list):
- acne
- androgenetic alopecia
- hirsutism
- seborrheic dermatitis
How the claim set scales across dependent claims
- Claim 1: covers any of the four pathologies as the “pathology affecting the skin and/or the cutaneous appendages” by labeling the pathology set in the claim itself.
- Claims 3–6: the dependent claims simply restate the pathology selection, mapping to topical administration (via Claim 2).
For compositions:
- Claim 7: same four pathologies and the same polymorph definition.
- Claims 9–12: restate the pathology selection, again with topical administration via Claim 8.
Topical route is a major narrowing in dependent coverage
Route limitation appears in:
- Claim 2 (topical application implied by “applied topically”)
- Claim 8 (topical application)
Then additional dosage-form dependent claims (Claim 14 and Claim 15) narrow further to cream/gel/ointment/lotion/paste formats.
What formulation and dosage forms are protected (and which aren’t) by this patent?
Answer: The protected compositions include those in tablet/capsule/powder/pellet/suspension/emulsion/cream/gel/ointment/lotion/paste forms (Claim 14), with topical limitation on the specific subgroup covered by Claim 15.
Dosage form list in Claim 14
A composition of Claim 7 can be any of:
- tablet
- capsule
- powder
- pellet
- suspension
- emulsion
- cream
- gel
- ointment
- lotion
- paste
Topical-only subset in Claim 15
Claim 15 limits Claim 14’s scope to topical application formats:
- powder, suspension, emulsion, cream, gel, ointment, lotion, paste
(Claim 15 does not include tablets/capsules/pellets as a topical subset)
Excipients: a defined example list
Claim 13 includes specific excipients:
- propylene glycol
- cetylic alcohol
- glyceryl monostearate
- liquid paraffin
- or combinations
This is not stated as an exhaustive list; it is a “wherein at least one excipient is [one of these or a combination]” style limitation, so the formulation must include at least one of the listed excipients to satisfy that dependent claim.
Optional solubilized cortexolone-17α-propionate (Claim 16–20)
Claim 16 adds a composition feature:
- “further comprises solubilized cortexolone-17α-propionate.”
Then Claim 17 and Claim 18 specify concentration bands:
- Claim 17: solubilized cortexolone-17α-propionate at 0.1% to 2% by weight
- Claim 18: solubilized + crystalline form III together at 0.1% to 2% by weight OR 0.2% to 1% by weight
Claim 19 and Claim 20 then extend to systems that include other crystalline forms (I, II, IV):
- Claim 19: solubilized + crystalline form III together with any of forms I, II, or IV, where total (solubilized + form III, with the mixture including the other forms) is 0.1% to 2% or 0.2% to 1% by weight.
- Claim 20: same but “comprise 1% by weight.”
What are the key claim “hooks” for infringement and for design-around risk?
Answer: The strongest hooks are (1) the DRX-based polymorph definition, (2) the indication set (four named conditions), and (3) the explicit acceptance of other polymorphs and solubilized drug, which reduces easy avoidance by “blending around.”
Hook 1: Polymorph identity via DRX
If a competitor markets a formulation using a different polymorph, they must be able to show the material does not meet the DRX criteria for crystalline form III (FIG/peak set). The claims are written to be satisfied when the DRX pattern matches the specified figure patterns or the “at least peaks” set.
Hook 2: Allowed combinations reduce “mixing defense”
Claim 19 and 20 remove a common design-around strategy: mixing polymorphs to argue “it’s not the single form.” The claims cover presence of crystalline form III even when other crystalline forms are present.
Hook 3: Solubilized drug does not avoid coverage
Claim 16 onward makes clear that adding solubilized cortexolone-17α-propionate does not steer out of the claim. Coverage remains if crystalline form III is present and the concentration bands are met for the solubilized and crystalline form III combinations.
Hook 4: Route and formulation dependent claims are layered, not exclusive
- Claim 1 is a method of treatment by administering crystalline form III (route not restricted there).
- Claim 2 narrows that to topical.
- Claim 7/8 provide parallel layers for compositions.
Thus a competitor using crystalline form III in non-topical routes could still risk Claim 1/7 coverage for the core method, depending on the actual claim construction and evidence.
How many distinct claim “positions” exist across the independent and dependent set?
Answer: Two independent claim “positions” plus multiple dependent layers.
Independent positions
- Claim 1: method using crystalline form III itself (no excipient requirement stated in the independent)
- Claim 7: method using a composition containing excipient + crystalline form III
Dependent positions (sub-coverage)
- Topical administration: Claim 2; Claim 8
- Indication selection: Claims 3–6; Claims 9–12
- Excipients example set: Claim 13
- Dosage formats: Claim 14; topical subset in Claim 15
- Solubilized active + concentration bands: Claims 16–18
- Mixtures with other polymorphs I/II/IV + concentration bands: Claims 19–20
This structure is typical of crystalline form assets: strong identity definition in the independent claims, then formulation breadth to cover likely commercial products.
What does the patent landscape likely look like for cortexolone-17α-propionate crystalline forms?
A complete “landscape” requires bibliographic data (filing dates, other US patents in the same family, continuations, and Orange Book listings). That information is not provided here, so a full landscape cannot be constructed.
What can be concluded from claim language alone is that the broader family likely includes:
- claims for other crystalline forms (I, II, IV) because Claim 19/20 explicitly reference them;
- claims that define DRX identity for each form; and
- formulation claims that incorporate those forms either alone or with solubilized drug.
Evidence of co-existing polymorph coverage inside the claims
Claim 19 and Claim 20 explicitly reference crystalline forms I, II, or IV. That indicates the inventive work for form III sits in a polymorph portfolio.
When does this patent lose exclusivity (expiration timeline)?
A reliable expiration timeline cannot be produced from the claims alone because it depends on:
- priority date(s),
- filing date,
- whether there were any terminal disclaimers,
- any patent term adjustment,
- and potential PTA/PTA caps.
No such date data is provided.
What is the Orange Book status of US 10,159,682?
Orange Book status cannot be determined from claims alone. Orange Book listing and patent code(s) depend on the specific FDA application reference product, NDA/ANDA/BLA linkages, and listing events.
No such information is provided.
How strong is the patent estate for competitors seeking to market cortexolone-17α-propionate products?
On claim strength mechanics, US 10,159,682 has three strengths and two typical vulnerabilities.
Strengths
-
Analytical definition is built into the claims
The “FIG” and “at least peaks” language supports enforcement with PXRD characterization.
-
Coverage extends beyond “pure form III”
Mixtures with other crystalline forms are still within Claim 19/20.
-
Coverage extends to many formulation formats
Tablets/capsules and multiple semi-solids are included in Claim 14, though topical is the more commercially relevant lane.
Vulnerabilities (claim-construction risk points)
-
Polymorph delineation can be challenged analytically
Competitors may attack whether their material meets the “at least peaks” requirements or matches FIG patterns, especially where polymorph mixtures and measurement conditions vary.
-
Indication list is limited to four named conditions
If a product targets other dermatologic or hair growth indications, the method claims may not read unless the treated pathology falls within the claim’s defined set.
What generic entry risks exist for formulations that contain crystalline form III?
Answer: High risk for any product that uses crystalline form III as defined and targets any of the four named indications, including topical products, and including products that also contain other polymorphs and/or solubilized drug within the claimed concentration relationships (for dependent claim coverage).
Entry risk is highest when:
- the active crystalline form is formulated as crystalline form III (DRX match),
- the product is intended for acne/androgenetic alopecia/hirsutism/seborrheic dermatitis, and
- the dosage form and excipient system falls within the dependent claims (topicals and common excipient set for Claim 13).
How does this claim set handle “mixtures” and “co-amorphous” or “other forms” questions?
The claims explicitly permit the presence of crystalline forms I, II, or IV together with crystalline form III (Claim 19/20). That reduces a common avoidance route.
They do not explicitly address:
- co-amorphous compositions,
- hydrates/solvates defined separately from crystalline forms I/II/III/IV,
- or metastable polymorph transformations over storage.
Those issues go to infringement evidence and claim construction, but they are not resolved solely from the provided claim text.
Which product types are most likely to infringe based on the dependent claims?
Most likely are topical dermatology products intended for the listed indications that contain crystalline form III either:
- as the primary solid-phase drug (Claim 1/2 path), or
- embedded in semi-solid formulations (cream/gel/ointment/lotion/paste) (Claim 14/15 path), and
- possibly combined with solubilized cortexolone-17α-propionate and/or other polymorphs (Claim 16–20).
Key Takeaways
- US 10,159,682 is centered on a polymorph identity: crystalline form III of cortexolone-17α-propionate defined by PXRD DRX patterns (FIG 7/10/13 or at least peaks at ~6.2, 12.6, 14.1, 14.3, 16.0, 22.4, 23.7° 2θ).
- The patent’s treatment scope covers four skin/cutaneous pathologies: acne, androgenetic alopecia, hirsutism, and seborrheic dermatitis.
- Topical use and a wide set of formulation formats are covered via dependents, including cream, gel, ointment, lotion, and paste.
- The claims explicitly cover mixtures with other crystalline forms (I/II/IV) and include embodiments with solubilized cortexolone-17α-propionate plus crystalline form III, including concentration bands.
- Enforcement leverage is highest where competitors rely on analytical proof that their active is not crystalline form III under the DRX definition.
FAQs
-
Does US 10,159,682 cover formulations that contain both crystalline form III and crystalline form I/II/IV?
Yes. Claims 19–20 expressly cover compositions where crystalline forms I, II, or IV are also present alongside crystalline form III.
-
Is topical application required for infringement of the independent claims?
Not for Claim 1/7 as written. Topical is required in dependent claims (Claim 2 and Claim 8), which narrows those specific dependent embodiments.
-
What concentration ranges are claimed for solubilized cortexolone-17α-propionate and crystalline form III?
Solubilized active is claimed at 0.1% to 2% by weight (Claim 17). Combined solubilized + crystalline form III is claimed at 0.1% to 2% or 0.2% to 1% by weight (Claim 18), and also at 1% by weight (Claim 20).
-
Which excipients are explicitly named in the patent?
Claim 13 lists propylene glycol, cetylic alcohol, glyceryl monostearate, liquid paraffin, or combinations.
-
What is the strongest analytical test competitor teams would use to assess infringement risk?
PXRD/DRX characterization targeted to the claimed “FIG 7/10/13” patterns and/or the “at least peaks” set at about 6.2, 12.6, 14.1, 14.3, 16.0, 22.4, and 23.7 degrees 2theta.
References
- US Patent No. 10,159,682 (claims as provided).